Catalent catches the cold chain wave

Cold chain competition is heating up, especially with Catalent's announcement Wednesday of facility expansions to keep pace with increasing customer demand. The expansions affect the U.S., U.K. and Germany.

"Steadily increasing numbers of biological products in development, particularly in prefilled syringes, are fueling the need for refrigerated storage and distribution," said VP/GM Frank Lis, in an announcement.  The move targets "all major areas" of storage and distribution, including 2 to 8 degree Celsius and -80 degree Celsius capabilities, with a tripling of storage and distribution space in some cases. Separately, Catalent had announced about a month ago that it was expanding its controlled substance clinical supply capacity.

We reported just last week on the efforts of the Indianapolis International Airport to bolster its standing as a cold-chain hub by hosting temperature-sensitive-service heavyweights DB Schenker, FedEx, Cargolux and Pace Air Freight.  And in June, DHL reported the conclusion of a pilot and subsequent rollout of a cold-chain track/trace system based on a temperature sensor from Sentry. DHL reported in April a deal with Cryoport, maker of frozen-product shipping containers.

Meanwhile, India's Hyderabad Airport opened a Pharma Zone late last year that includes a temperature-controlled facility with a dedicated area for 2 to 8 degree Celsius storage.

- see the cold chain release
- here's Catalent's controlled substance release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.